



23 March 2004

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

Dear Sir

COMPANY UPDATE – NEWSLETTER

Please find attached a shareholder newsletter for Resonance Health Limited which was distributed to shareholders along with the Shareholder Share Purchase Plan.

Yours truly,

Tony Fitzgerald
Managing Director



19 March 2004

Dear Shareholder,

On behalf of the board of Resonance Health Limited (RHT), I am pleased to provide an update of our activities for your information.

As most of you will be aware, Resonance Health was created out of the old GEO2 Limited structure. On 12 November 2003, a new board of directors was appointed and the company acquired a controlling interest in the award winning **FerriScan Technology** – a novel, non-invasive liver diagnosis technology, designed to replace liver biopsy for the measurement of iron overload in the liver, and with potentially broader applications in other areas of liver disease such as fibrosis caused by hepatitis.

The liver is the major site of iron deposition in iron overload diseases and as a result is important in the detection and treatment of iron overload. Hereditary Haemochromatosis (HHC) is the most common form of iron overload disease in the western world, affecting approximately 1 in 200 people of European descent. In the USA, the incidence rate of HHC may be as high as 1 in 100 or approximately 4.0 million people. If left untreated, iron toxicity is a major cause of organ damage; particularly the liver, heart and pancreas.

FerriScan uses safe MRI technology and its own proprietary software to provide a safe, fast and reliable measure of a patient's liver iron concentration, allowing clinicians to assess the appropriate treatment (currently frequent phlebotomy "bleeding"). Part of the attraction of FerriScan is that the analysis can be undertaken here in Australia on liver scans transmitted from anywhere around the world.

The previous "gold standard" measurement for iron measurement was an invasive, unpleasant procedure known as liver biopsy, where a piece of liver is extracted from the patient by large gauge needle. Internal bleeding is a not uncommon side effect of this procedure. The FerriScan technology is currently being used on a test and research basis at more than 25 MRI centres around the world, including the USA, South America, Europe and Asia. In addition, a major multinational pharmaceutical company is using the FerriScan test to develop clinical data for iron measurement of patients in a phase III clinical trial.

We believe FerriScan has an exciting and near term profitable future in the area of iron overload and exciting prospects in some other major disease areas particularly hepatitis. The company is continuing to expand the number of collaborations with researchers in areas where abnormal iron levels may be an indicator to other diseases or conditions including diabetes, heart disease and Alzheimers disease.

Resonance anticipates that the commercial roll out of the FerriScan technology in Australia and the UK will commence in the second half of this calendar year. The timing of this roll out is dependent upon receipt of Therapeutic Goods Administration (TGA) registration of the FerriScan test. An application for registration of the FerriScan test is expected to be lodged with the TGA in early April 2004 with registration targeted by the third quarter of 2004. At around this time we will also apply for US FDA approval to market FerriScan in this major market.

The directors have indicated that they will be participating in the Share Purchase Plan. As a director and shareholder of Resonance Health, I actively encourage you to support the company's endeavours in this very worthwhile activity and to participate in the proposed Share Purchase Plan.

If you would like further information about Resonance Health and FerriScan please visit our web sites at:

www.resonancehealth.com www.ferriscan.com

Alternatively, please call the Company Secretary, Evan Cross or myself with any questions you may have.

Yours truly,

Tony Fitzgerald
Managing Director